Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Patients with celiac disease face increased risk of mortality

New research indicates that patients with lesser degrees of celiac disease-related symptoms, such as intestinal inflammation or latent celiac disease, have a modestly increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Damaged heart tissue is significantly reduced with supersaturated oxygen

Results of a clinical trial published today in Circulation: Cardiovascular Interventions demonstrate that an infusion of blood that is "supersaturated" with oxygen (SS02) can reduce the amount of damaged heart muscle immediately following a life-threatening heart attack

16 Sep 2009

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion titled "Cardiovascular Disease in Survivors of Childhood Cancer" presented by Dr. Ming Hui Chen, Director, Stress Echocardiography Program and Program for Cardiac Health in Cancer Survivors, Children's Hospital Boston.

15 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

NMQF launches the P.A.D. Atlas database that maps peripheral arterial disease prevalence by zip code

The National Minority Quality Forum (NMQF), one of the nation's leading voices in the health disparities discussion, is launching the P.A.D. Atlas, a database that maps by zip code peripheral arterial disease (P.A.D.) prevalence down to the street level, with the P.A.D. Coalition and support from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.

15 Sep 2009

Critical event experienced by 1 in 20 acutely-ill patients during air-medical transport

During air-medical transport of acutely-ill patients, 1 in 20 experience a critical event such as death, major resuscitation or blood pressure deterioration according to a new study http://www.cmaj.ca/press/cmaj080886.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

New book on human genetics helps to unravel complex human diseases

Many human diseases-including Alzheimer's disease, schizophrenia, cancer, and cardiovascular disease-are caused by multiple genetic variants and the interaction of those variants with the environment. Because such diseases lack a clear-cut inheritance pattern, sophisticated technological approaches and statistical analyses are required to determine their underlying cause.

15 Sep 2009

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

The Heart Failure Society of America's (HFSA) 13th Annual Scientific Meeting convened Sunday, September 13, 2009 at the Hynes Convention Center in Boston. This three-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with this condition.

15 Sep 2009

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.

14 Sep 2009

IVIS Lumina XR in vivo imaging system from Caliper Life Sciences

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family.

14 Sep 2009

Final results of SAPHRIS clinical study released

Schering-Plough Corporation today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study.

14 Sep 2009

Scientific program to treat and prevent mental disorders

Mental disorders are a global problem and represent one of the biggest challenges for health care systems. In the world, there are some 500 million people suffering from mental disorders, and in the European Union, mental disorders range as one of the leading causes of disease burden.

14 Sep 2009

Research data reveals why women discontinue treatment with current osteoporosis therapies

Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

Scientists to get funding from The European Research Council

The European Research Council (ERC) expects to fund some 240 top researchers in its second prestigious ERC Starting Grant competition. This new wave of grantees follows the 299 researchers who received grants in the first Starting Grant competition in 2007.

11 Sep 2009

End stage renal disease can be delayed by early identification of CKD

Early identification of individuals with chronic kidney disease (CKD) can delay the onset of end stage renal disease (ESRD) and the need for chronic dialysis treatments. The incidence of CKD continues to grow, and early identification and intervention are critical to manage this costly disease.

11 Sep 2009

Children with larger waists are more at risk of developing cardiovascular disease later in life

Children with more fat around their midsections could be at a higher risk of developing cardiovascular disease later in life, researchers say.

11 Sep 2009

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

Researchers at The Medical College of Wisconsin in Milwaukee have identified the genetic region in rats responsible for cardiovascular collapse during anesthesia. While it is well known that people have different cardiovascular sensitivity to anesthesia causing some to collapse even when low doses are administered, the mechanism responsible for this susceptibility is not clear.

11 Sep 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Patients with celiac disease face increased risk of mortality

Damaged heart tissue is significantly reduced with supersaturated oxygen

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

NMQF launches the P.A.D. Atlas database that maps peripheral arterial disease prevalence by zip code

Critical event experienced by 1 in 20 acutely-ill patients during air-medical transport

New book on human genetics helps to unravel complex human diseases

HFSA's 13th Annual Scientific Meeting focuses on causes and treatment of heart failure

Public health policy should stress on reduction in sodium intake

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

IVIS Lumina XR in vivo imaging system from Caliper Life Sciences

Final results of SAPHRIS clinical study released

Scientific program to treat and prevent mental disorders

Research data reveals why women discontinue treatment with current osteoporosis therapies

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Scientists to get funding from The European Research Council

End stage renal disease can be delayed by early identification of CKD

Children with larger waists are more at risk of developing cardiovascular disease later in life

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in